Federated Hermes
CRNX

Federated Hermes’s Crinetics Pharmaceuticals CRNX Stock Holding History

Federated Hermes’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.96M Buy
105,756
+89,508
+551% +$3.33M 0.01% 898
2026
Q1 		$590K Buy
+16,248
New +$726K ﹤0.01% 1255
2024
Q3 		– Sell
-15,768
Closed -$706K – 2078
2024
Q2 		$706K Buy
15,768
+12,291
+353% +$568K ﹤0.01% 1217
2024
Q1 		$163K Buy
3,477
+3,459
+19,217% +$135K ﹤0.01% 1525
2023
Q4 		$640 Sell
18
-6
-25% -$184 ﹤0.01% 2001
2023
Q3 		$714 Buy
+24
New +$495 ﹤0.01% 2024
2022
Q2 		– Sell
-25,482
Closed -$559K – 2172
2022
Q1 		$559K Buy
25,482
+646
+3% +$13.1K ﹤0.01% 1421
2021
Q4 		$706K Buy
+24,836
New +$612K ﹤0.01% 1379
2020
Q3 		– Sell
-64
Closed -$1K – 2261
2020
Q2 		$1K Sell
64
-29
-31% -$494 ﹤0.01% 2134
2020
Q1 		$1K Buy
+93
New +$1.91K ﹤0.01% 2095

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes's CRNX Position: Q2 2026 in Review

Federated Hermes increased its Crinetics Pharmaceuticals (CRNX) stake by 551% in Q2 2026, buying an estimated $3.33M and bringing the position to 105,756 shares worth $3.96M. The position accounts for 0.01% of the portfolio, ranked #898.

Federated Hermes first reported a position in CRNX in Q1 2020 and has held it in 10 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Federated Hermes held 105,756 shares of Crinetics Pharmaceuticals worth $3.96M as of Q2 2026.
  • Federated Hermes bought 89,508 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $3.33M.
  • Crinetics Pharmaceuticals made up 0.01% of Federated Hermes's portfolio in Q2 2026, its #898 holding.
  • Federated Hermes first reported a position in Crinetics Pharmaceuticals in Q1 2020 and has held it in 10 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.